Apremilast

證據等級: L5

預測適應症: 0 個

Apremilast: Drug Repurposing Evaluation — TxGNN Predictions Pending

One-Sentence Summary

Apremilast (DrugBank: DB05676) is a selective phosphodiesterase 4 (PDE4) inhibitor with established use in inflammatory conditions such as psoriatic arthritis and plaque psoriasis, and is confirmed as marketed in Malaysia with 3 registered products. However, the current Evidence Pack contains no TxGNN-generated new indication predictions, and critical data — including regulatory label details, safety warnings, and mechanism of action — were not retrieved in this collection cycle. A complete drug repurposing evaluation cannot be issued until these gaps are resolved; a Hold decision is recommended pending re-collection.

Quick Overview

Item	Content
Original Indication	Not retrieved — regulatory label text absent from this Evidence Pack
Predicted New Indication	Pending — no TxGNN predictions present in this Evidence Pack
TxGNN Prediction Score	N/A
Evidence Level	N/A
Malaysia Market Status	✓ Marketed
Number of Registrations	3
Recommended Decision	Hold

Why is This Prediction Reasonable?

This section cannot be completed in the standard form because no TxGNN-predicted target indication is available in the current Evidence Pack (predicted_indications: []).

From publicly available pharmacological knowledge, Apremilast is a small-molecule PDE4 inhibitor that raises intracellular cyclic AMP (cAMP) levels, broadly modulating the production of inflammatory and anti-inflammatory mediators (e.g., reducing TNF-α, IL-17, IL-23 while increasing IL-10). This mechanism of action has potential relevance across a wide spectrum of chronic inflammatory diseases beyond its currently approved uses.

Once TxGNN predictions are generated, this section will assess the mechanistic plausibility of the top-ranked candidate indication(s) and their relationship to the approved inflammatory indication cluster.

Malaysia Market Information

The Evidence Pack records 3 registered products in Malaysia (NPRA query status: success), but all product-level fields — authorisation number, product name, dosage form, manufacturer, and approved indication text — were returned as empty in this collection run. The table below cannot be populated until NPRA registration details are re-queried.

Authorisation Number	Product Name	Dosage Form	Approved Indication
(not retrieved)	(not retrieved)	(not retrieved)	(not retrieved)

Action required: Re-query NPRA with drug name “APREMILAST” and retrieve full product detail records for all 3 licences.

Safety Considerations

Please refer to the package insert for safety information. Key warnings and contraindications were identified as a Blocking data gap (DG001) and were not retrieved in this evaluation cycle. No drug-drug interaction records were found in the DDI query (result: not_found, 0 interactions).

Conclusion and Next Steps

Decision: Hold

Rationale: The Evidence Pack is missing the three minimum requirements for a repurposing evaluation — TxGNN target indication predictions, populated regulatory label data, and safety information — making it impossible to assess therapeutic potential, mechanistic plausibility, or risk profile at this time.

To proceed, the following is needed:

[Blocking — DG001] Download and parse the NPRA / TFDA package insert PDF for Apremilast to extract key warnings and contraindications; this must be resolved before any safety assessment can begin
[High — DG002] Query the DrugBank API for DB05676 to retrieve the full mechanism of action (MOA) description
[Required] Run the TxGNN model pipeline for Apremilast (DB05676) to generate ranked new-indication predictions; without predictions, no repurposing target exists to evaluate
[Required] Re-query NPRA registration database to retrieve complete product details (authorisation numbers, product names, dosage forms, approved indications) for all 3 Malaysian licences
[Follow-up] Once a target indication is identified, run ClinicalTrials.gov and PubMed evidence collectors against the drug–disease pair to populate the clinical trial and literature evidence sections
[Follow-up] Reassign Evidence Level (L1–L5) and upgrade the decision recommendation (Go / Proceed with Guardrails) after all gaps above are closed

⚠️ Disclaimer: This report is for research reference only and does not constitute medical advice. Drug repurposing candidates require clinical validation before any therapeutic application.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.